Sleep organization is unaffected by caffeine in premature infants.
We performed 10-hour polysomnographic recordings in 15 neurologically normal and clinically stable 33- to 34-week postmenstrual age (PMA) neonates, 10 of whom had been treated >3 days with once-per-day oral caffeine citrate (5 mg/kg) given at approximately 2 PM. We analyzed (a) the usual sleep-wake variables, including wakefulness, active sleep, quiet sleep, and indeterminate sleep expressed as the number of episodes, duration, and percentage of total sleep time; (b) the duration and order of variable modifications during transitions between the main active sleep and quiet sleep states; and (c) the characteristics of morning data (before caffeine) compared with evening data (after caffeine). We found no significant differences between the controls and the infants receiving maintenance caffeine.
Curzi-Dascalova
Lilia
L
INSERM, EPI9935, Service de Physiologie, Service de Néonatologie, Hôpital Robert-Debré, Paris, France.
Aujard
Yanick
Y
Gaultier
Claude
C
Rajguru
Mandevi
M
D002110:Caffeine / Q000494:pharmacology* / Q000627:therapeutic use; D015148:Cardiotocography; D002951:Citrates / Q000494:pharmacology* / Q000627:therapeutic use; D004338:Drug Combinations; D004585:Electrooculography; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D017286:Polysomnography; D012890:Sleep / Q000187:drug effects*; D012891:Sleep Apnea Syndromes / Q000188:drug therapy
D002951:Citrates; D004338:Drug Combinations; D002110:Caffeine; C026189:caffeine citrate